China Biotech Podcast: Shanghai Policy, US Draft Biosecure Bill, MNCs' China Strategy
Policy, Legislation And Business
Executive Summary
Brian Yang, Dexter Yan and guest speaker Kevin Grogan from the UK discuss Shanghai's latest policy to spur biopharma investment, the US House's recent draft bill to restrict bio service providers from China, and multinationals' strategies in China and views on Chinese innovation.
The Shanghai government is aiming to spur investment in three areas, including biotech, which is slated to receive additional funding from the major Chinese city.
What are some of the implications of the policy? (Also see "Shanghai's Latest Policy To Boost VC/PE Activities Amid Sector Downturn" - Scrip, 25 Jan, 2024.)
Meanwhile, a US House draft bill, Biosecure, is aimed at restricting Chinese gene sequencing and bio service providers from participating in US government contracts, causing WuXi Biologics' Hong Kong-listed shares to tumble.
What could be some of the long term impacts on the biotech sector? (Also see "US Draft Bill Highlights Perceived China Biotech Threat" - Scrip, 30 Jan, 2024.)
Scrip UK-based managing editor Kevin Grogan also joins Brian Yang to discuss his recent coverage of AstraZeneca PLC and Sanofi, in which executives of these multinationals shed light on their views of China, rising Chinese innovation and other challenges.
2024年1月，上海市政府出台了《关于进一步促进上海股权投资行业高质量发展的若干措施》。这一政策推出的背景是什么？对于生物医药行业来说，其中有哪些亮点值得我们关注？
去年11月中美领导人旧金山峰会后，中美之间在健康领域有哪些最新进展？这个美国国会提议的生物领域提案，目前产生了哪些影响？长远来看，中美之间的科技合作和健康合作会怎样发展？
Scrip驻曼切斯特的编辑Kevin Grogan作为嘉宾加入讨论，他从最近采访阿斯利康商务拓展负责人Shaun Grady和赛诺菲首席执行官Paul Hudson分享了跨国药企对于中国市场的看法 (Also see "AstraZeneca Likes What Chinese Innovation Has To Offer" - Scrip, 6 Dec, 2023.) (Also see "Sanofi Chief Issues Warning To Innovation-Unfriendly EU" - Scrip, 2 Feb, 2024.)，对于中国创新的机会的把握，和一些挑战的理解。
更多往期节目，也可以在喜马拉雅上找到。
最后祝大家：新年快乐！下期节目见。